BioMed NVMainz Biomed NV may have taken a major step in early pancreatic cancer detection. The company reports that its multivariate RNA liquid biopsy test, licensed from Liquid Biosciences Inc. in March, achieved 100% sensitivity and 95% specificity in a feasibility study. The results suggest the test could detect cancer—and even precancerous lesions—earlier than current methods.
ADVERTISEMENT
Tag Archive for: pancreatic cancer
Molecular diagnostics specialist Mainz Biomed NV has inked a research collaboration with precision microbiome firm Microba Life Sciences Inc.